Disease relevance of AVEN

• 1) AVE and AVEN significantly increased with increasing body weight (BW) as has been reported previously, but no such correlation was found between AHR and BW [1].
• The aim of this study was to determine the two distinct antiapoptotic signals-survivin and aven-in acute leukemias and compare them with clinical and hematological findings and response to therapy [2].
• There was no important association between survivin or aven and performance status, lymphadenopathy or organomegaly [2].
• Aven overexpression: association with poor prognosis in childhood acute lymphoblastic leukemia [3].
• These findings demonstrate that Aven expression can predict prognosis in childhood ALL [3].

High impact information on AVEN

• Thus, Aven represents a new class of cell death regulator [4].
• RESULTS: Survivin was between 0.0 and 0.829 copy number/cell (median 0.0721, mean 0.5424301909 +/- 0.139799488589) and aven was between 0.0 and 0.853 copy number/cell (median 0.0124, mean 0.070335542 +/- 0.1524685709) [2].
• In this study, Aven expression in 91 children with acute lymphoblastic leukemia (ALL) was investigated for possible correlation with clinical features at diagnosis and treatment outcome [3].
• Aven expression was found to be higher in patients >or=10 years old or <1 year (P=0.003), and in patients with unfavorable cytogenetic abnormalities (P<0.001) [3].
• Comparing survivin and aven between EPO and MPS treatment groups showed no significance (P = .3027, .2171, respectively) [5].

Biological context of AVEN

• Real-time quantitative polymerase chain reactions were used to estimate survivin and aven gene expression at the total RNA level [5].

Other interactions of AVEN

• 2) VO2 at rest was found to be positively correlated with AVE and AVEN but not with AHR [1].

Analytical, diagnostic and therapeutic context of AVEN

• Real-time quantitative PCR was used and survivin and aven were detected at the messenger (m)RNA level [2].

References